Answers are grounded in this paper and cite their sources.
Identifies novel csf3r mutations causing moderate neutropenia in families, suggesting alternative pathways for neutrophil development.
To the Editor: The growth factor granulocyte colony-stimulating factor (G-CSF) has been described as a key regulator of neutrophil development by inducing proliferation, differentiation, and survival of myeloid progenitors. In case of infection, G-CSF stimulates emergency granulopoiesis.1 The receptor for G-CSF (G-CSF-R), encoded by CSF3R, is a member of the type I cytokine receptor superfamily. One of the major pathways activated upon G-CSF-R stimulation is the Janus kinase (JAK)-signal transducer and activators of transcription (STAT) pathway, leading to phosphorylation of STAT1, 3 and 5, which subsequently can induce transcription of their target genes.2 To date, 8 families with 11 (inherited) loss-of-function mutations in CSF3R in 10 patients have been reported (Table SI).3-10 These patients suffer from congenital neutropenia and cannot be treated with G-CSF due to refractoriness. The consequence of G-CSF-R deficiency for cellular differentiation, effector functions and signal transduction in human primary neutrophils have not been studied in detail. Genetic testing on the first patient with moderate-to-mild neutropenia was performed at the age of 40 (Fig 1A,B; panel I). She had been admitted with several infectious episodes for which intravenous antibiotics were prescribed. A bone marrow aspirate showed a left shift in granulopoiesis. Upon treatment with G-CSF (before genetic analysis was performed) no improvement in neutrophil count was repeatedly noticed (for patient history, see Supporting Information). Genetic analysis identified compound heterozygous mutations in CSF3R (NM_000760.3) with a novel conserved missense variant (c.359G>A, p.(G120D); CADD score 29) and a nonsense variant with a population frequency of approximately 1:5000 (gnomAD AF = 0·0003; BRIDGE/GEL AF = 0·0007 at c.1640G>A, p.(W547*)). A second case, from a consanguineous family, had mild neutropenia and suffered from unexplained febrile episodes for about 5 years (Fig 1A,B; panel II). Genetic analysis identified a homozygous missense mutation in CSF3R (c.1318C>T, p.(R440*)). Out of 4 other siblings, one was also homozygous (patient 3), one a heterozygous carrier, and one did not have the genetic variant. Whilst being mildly neutropenic, patients 2 and 3 were clinically not severely affected (Fig 1B; Supporting Information). All reported inherited loss-of-function mutations in CSF3R are present in the extracellular domain of CSF3R, of which 4 are localized near or in the conserved WSXWS motif (Fig 1C). The mutations in patient 1 were localized in the so-called CRH region and third FNIII domain, respectively (Fig 1C). The mutation in the FNIII domain leading to a stop-codon (p.W547*) has been previously described.5 The homozygous mutations in patients 2 and 3 are localized in the second FNIII domain and lead to a premature stop. Circulating neutrophils demonstrated a normal morphology and segmented nuclei (Fig 1D). Neutrophils from the UK samples showed some apoptotic cells, which can be explained by the shipment of blood samples to our laboratory. Flow cytometric analysis did not reveal differences in expression of the neutrophil maturation marker EGF module-containing mucin-like hormone receptor 3 (EMR3)11 between control and patient neutrophils (Figure S1). Label-free quantitative mass spectrometry-based proteomics was performed on neutrophils of patients, patients’ family members, and controls. No large differences between granule proteins and components of the NADPH-oxidase complex were found, indicating intact neutrophil development at all stages12 (Figure S2A,B). Of the 2,849 proteins which were identified and quantified, 10 proteins showed altered expression between patients and controls (Figure S3). Altered expressed proteins include proteoglycan 3 (PRG3), eosinophil cationic protein (RNASE3) and eosinophil peroxidase (EPX), indicative of some eosinophil contamination which was also observed by cytospin (i.e. 5·3 ± 3·3% in controls vs. 10·3 ± 2·6% in patients). Immunostaining of G-CSF-R showed greatly reduced expression on patient neutrophils. In the second pedigree, flow cytometry showed intermediate expression on the heterozygous family members, while the unaffected sibling had G-CSF-R surface staining comparable to unrelated healthy controls (Fig 2A and Figure S4). Intermediate G-CSF-R expression did not result in reduced neutrophil counts (data not shown). G-CSF is important for neutrophil survival. Although granulocyte-macrophage colony-stimulating factor (GM-CSF) has overlapping functions with G-CSF, it signals via a different receptor (GM-CSF-R).13 When comparing the response to both growth factors, G-CSF failed to induce survival of patient neutrophils (Fig 2B and Figure S5). Additionally, we tested the priming capacity of G-CSF by formyl-Met-Leu-Phe-induced reactive oxygen species (ROS) production in neutrophils. Again and in contrast to control cells, patient neutrophils did not show an enhanced ROS production upon pre-incubation with G-CSF while being responsive to GM-CSF (Fig 2C). To confirm the absence of G-CSF-R signalling, STAT3 phosphorylation was evaluated upon incubation with GM-CSF or G-CSF. Both control and patient neutrophils showed STAT3 phosphorylation upon GM-CSF stimulation, whereas only control neutrophils demonstrated STAT3 phosphorylation after G-CSF stimulation (Fig 2D and Figure S6). These data show that the mutations in CSF3R in these patients resulted in lack of G-CSF-R expression and function. Although the missense variant (c.359G>A, p.(G120D)) in patient 1 might result in residual expression of G-CSF-R, functional analysis on primary neutrophils and in-vitro and in-vivo refractoriness to G-CSF proves that this missense variant has a deleterious impact on receptor signalling. Despite lack of G-CSF-R expression and signalling in neutrophils, the neutropenia in these patients is moderate-to-mild. This finding implies that the myeloid progenitors are able to generate a pool of normal differentiated and functionally mature neutrophils. This is reminiscent of G-CSF-R knockout models in mice, in which neutrophil counts were decreased for 50% at most.14 Bone marrow samples of patients were not available for functional analysis. Still, there is a lack of immediate response to G-CSF-induced release of neutrophils from the bone marrow upon infection or exogenous administration, as exemplified in the first patient. In healthy controls, there is low expression of G-CSF-R on bone marrow neutrophils compared to circulating neutrophils as assessed by flow cytometry (Figure S7). These results suggest that G-CSF-R is present on committed progenitors for accelerating neutrophil production required for ‘emergency neutrophilia’ at the final stage of segmented neutrophils and immediate release of the bone marrow reserve pool. G-CSF-induced mobilization of hematopoietic progenitor cells coincides with cleavage of C-X-C Motif Chemokine Receptor 4 (CXCR4) and its ligand (stromal cell-derived factor 1, SDF-1) by neutrophil proteases in the bone marrow.15 As the CXCR4/SDF-1 axis is also implicated in neutrophil retention,16 it is expected that the same mechanism applies for the egress of mature neutrophils. The increase of G-CSF-R expression at the final stage of neutrophil development would also be compatible with the strong pro-survival effect of G-CSF on circulating and bone marrow neutrophils (data not shown). In the absence of G-CSF-R, neutrophil differentiation in the bone marrow can still proceed under the influence of other factors like GM-CSF, interleukin-6 and as yet unidentified factors 13. However, these factors combined do not seem to fully compensate for G-CSF deficiency because neutrophil production remains quantitatively impaired in individuals which lack GCSF-R expression. In sum, our data support the notion that the major role of G-CSF in neutrophil expansion and release may be during inflammatory responses when a larger bone marrow output and prolonged survival is required to cope with serious infections but not for neutrophil differentiation per se. We are most grateful to the patients and their families for their collaboration. We thank Ida H. Hiemstra and Cathelijn E.M. Aarts for isolation of bone marrow neutrophils and flow cytometric analysis. We thank NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR BioResource centres, NHS Trusts and staff for their contribution. We thank the National Institute for Health Research and NHS Blood and Transplant. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. We would like to thank the members of the NBR-RD PID Consortium: Zoe Adhya, Hana Alachkar, Carl E. Allen, Ariharan Anantharachagan, Richard Antrobus, Gururaj Arumugakani, Chiara Bacchelli, Helen E Baxendale, Claire Bethune, Shahnaz Bibi, Barbara Boardman, Claire Booth, Matthew Brown, Michael J Browning, Mary Brownlie, Matthew S Buckland, Siobhan O Burns, Oliver S Burren, Anita Chandra, Ivan K. Chinn, Hayley Clifford, Nichola Cooper, Godelieve J de Bree, E Graham Davies, Sarah Deacock, John Dempster, Lisa A Devlin, Elizabeth Drewe, J David M Edgar, William Egner, Shuayb El Khalifa, Tariq El-Shanawany, James H R Farmery, H Bobby Gaspar, Rohit Ghurye, Kimberly C Gilmour, Sarah Goddard, Pavels Gordins, Sofia Grigoriadou, Scott J Hackett, Rosie Hague, Lorraine Harper, Grant Hayman, Archana Herwadkar, Stephen Hughes, Aarnoud P Huissoon, Stephen Jolles, Julie Jones, Yousuf M Karim, Peter Kelleher, Sorena Kiani, Nigel Klein, Taco W Kuijpers, Dinakantha S Kumararatne, James Laffan, Hana Lango Allen, Sara E Lear, Hilary Longhurst, Lorena E Lorenzo, Paul A Lyons, Jesmeen Maimaris, Ania Manson, Elizabeth M McDermott, Hazel Millar, Anoop Mistry, Valerie Morrisson, Sai H K Murng, Iman Nasir, Sergey Nejentsev, Sadia Noorani, Eric Oksenhendler, Mark J Ponsford, Waseem Qasim, Ellen Quinn, Isabella Quinti, Paula Rayner-Matthews, Alex Richter, Crina Samarghitean, Ravishankar B Sargur, Sinisa Savic, Suranjith L Seneviratne, W A Carrock Sewell, Fiona Shackley, Olga Shamardina, Ilenia Simeoni, Kenneth G C Smith, Emily Staples, Hans Stauss, Cathal L Steele, Kathleen E Stirrups, James E Thaventhiran, David C Thomas, Moira J Thomas, Adrian J Thrasher, John A Todd, Anton T J Tool, Salih Tuna, Rafal D Urniaz, Steven B Welch, Lisa Willcocks, Sarita Workman, Austen Worth, Nigel Yeatman, Patrick F K Yong. Contribution: E.G.G.S., S.O.B. and T.W.K. wrote the manuscript; E.G.G.S., A.T.J.T., and T.W.K. designed the experiments. E.G.G.S., and A.T.J.T. performed experiments and analyzed the data; S.O.B. and T.W.K. analyzed clinical data; NIHR BioResource, J.M. and K.v.L. performed DNA analysis; I.C.K. and F.P.J.v.A. performed mass spectrometry analysis; and all authors read, revised and approved the manuscript. The authors declare that they have no relevant conflicts of interest. This study was funded in part by the European Union's Horizon 2020 research and innovation programme under Grant Agreement No. 668303, Program on Prevention Outcomes Practices Grant PPOP-12-001 and the Center of Immunodeficiencies Amsterdam Grant CIDA-2015. Figure S1. EMR expression of primary neutrophils was assessed by flow cytometry. (A) Mean fluorescence intensity (MFI) is normalized to the control neutrophils of that day. (mean + range, n = 2 of patient 1 and n = 1 of patient 2 and 3). (B) Gating strategy to select neutrophils (P1) based on FSC/SSC. Figure S2. Mass spectrometry analysis of unstimulated neutrophils. (A) Granule proteins and (B) NADPH-oxidase complex proteins do not show significant differences between control vs patient neutrophils. Figure S3. Proteomic analysis of unstimulated G-CSFR-deficient primary neutrophils. (A) Hierarchical clustering based on z-scored label-free quantification (LFQ) intensity and heatmap of significantly altered proteins. (B) Log2 LFQ values of significant proteins found in patients vs controls. Eosinophil contamination was 5·3 % in control samples (n = 4) and 10·3% in patient samples (n = 4). NL = samples derived from The Netherlands, UK = samples derived from the United Kingdom, Ctrls = controls, Sib = sibling, htz = heterozygous, wt = wild type Figure S4. G-CSF-R expression on primary neutrophils was assessed by flow cytometry. (A) Mean fluorescence intensity (MFI) from patient 1 (n = 1) and (B) MFI from patient 2 (mean + range, n = 3) and patient 3 (mean + range, n = 2). Figure S5. Flow cytometry gating strategy for neutrophil viability measurement. Gating strategy of patient 3 is shown as representative. Annexin-V-FITC is used as apoptosis marker, while TO-PRO-3-APC is used as extracellular DNA marker. Figure S6. Phosphorylation of STAT-3 in neutrophils upon stimulation with GM-CSF and G-CSF (time of stimulation shown in minutes) was assessed by Western blot. GAPDH was used as loading control. Western blot of patient 1 and his mother. Figure S7. G-CSFR expression on blood neutrophils (n = 18) and on myeloid progenitors (n = 3) and segmented mature neutrophils (n = 3) in the bone marrow as assessed by flow cytometry. Geometric mean fluorescence intensity (gMFI) is depicted. Table SI. Summary of earlier described patients with inherited loss-of-function mutations in CSF3R. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Sprenkeler et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: